Market Place
Sourcing Support
Vicore`s IPF drug improves lung function in phase 2 win
20 May 2024 //
FIERCE BIOTECH
Vicore doses first patient in trial of endothelial dysfunction
05 May 2023 //
CLINICAL TRIALS ARENA
Vicore begins vital endothelial dysfunction study
04 May 2023 //
PHARMATIMES
Vicore initiates clinical proof-of-concept study of endothelial dysfunction
03 May 2023 //
BUSINESSWIRE
Vicore announces first patient enrolled in COMPANION;a digital therapeutic study
05 Dec 2022 //
PRNEWSWIRE
Vicore announces new data from IPF AIR trial further strengthening the benefit
03 Nov 2022 //
CISION
Vicore`s digital therapeutic shows nearly 50% anxiety reduction in pilot study
06 Oct 2022 //
PRNEWSWIRE
Vicore announces that C21 promotes vascular function in humans
22 Sep 2022 //
PRNEWSWIRE
Vicore IPF interim data selected as an oral "late-breaker" at the ERS congress
17 Aug 2022 //
PRNEWSWIRE
Vicore announces first human dosed with novel ATRAG, C106
16 Jun 2022 //
PRNEWSWIRE
Vicore Pharma begins patient dosing in COMPANION clinical study
22 Apr 2022 //
PHARMABIZ
Vicore launches COMPANION in idiopathic pulmonary fibrosis
20 Apr 2022 //
PRNEWSWIRE
Vicore strengthens rare lung disease pipeline with PAH indication
09 Mar 2022 //
PRNEWSWIRE
Vicore adds to rare lung disease pipeline with PAH indication
09 Mar 2022 //
PHARMAFILE
Vicore takes major step towards clinical platform company targeting AT2R
22 Feb 2022 //
PRNEWSWIRE
Vicore`s AIR study suggests that C21 improves lung function in IPF patients
10 Feb 2022 //
PRNEWSWIRE
Vicore announces positive results from ATTRACT phase 2 extension study of AT2R
03 Nov 2021 //
PHARMABIZ
Vicore`s C21 reduces long-term lung injury after COVID-19
02 Nov 2021 //
PRNEWSWIRE
Lancet`s EClinicalMedicine publishes phase 2 data on C21 in COVID-19
25 Oct 2021 //
PRNEWSWIRE
Vicore obtains SARS coronavirus patent for C21 in the USA
22 Sep 2021 //
PRNEWSWIRE
Vicore To Host Key Opinion Leader Webinar On C21 For The Treatment of IPF
22 Sep 2021 //
PRNEWSWIRE
Vicore starts dosing first COVID-19 patients in global phase 3 trial ATTRACT-3
17 Sep 2021 //
PRNEWSWIRE
Vicore announces participation in investor meetings during June 2021
15 Jun 2021 //
PRNEWSWIRE
Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19
11 Jun 2021 //
PRNEWSWIRE
Vicore Pharma`s drug candidate C21 dilates peripheral resistance vessels
11 Mar 2021 //
PRNEWSWIRE
Vicore Pharma`s drug candidate C21 dilates peripheral resistance vessels
10 Mar 2021 //
PRNEWSWIRE
Vicore Pharma Holding AB (publ) publishes the year-end report for 2020
26 Feb 2021 //
PRNEWSWIRE
Positive data from Phase II study ATTRACT in patients with COVID-19 published
01 Feb 2021 //
PRNEWSWIRE
Vicore Pharma’s C21 med shows promise in COVID-19 study
23 Dec 2020 //
PHARMATIMES
Vicore Pharma’s C21 med shows promise in COVID-19 study
23 Dec 2020 //
MEDDDYA
Vicore Pharma’s C21 med shows promise in COVID-19 study
22 Dec 2020 //
PHARMATIMES
Vicore Pharma’s C21 med shows promise in COVID-19 study
22 Dec 2020 //
MEDDDYA
Positive results show that C21 can become an important complement to COVID-19
22 Dec 2020 //
PRNEWSWIRE
Vicore Pharma reports positive top line data from the ATTRACT clinical study
08 Dec 2020 //
PRNEWSWIRE
Vicore recruits the first patient in the phase II Proof-of-Concept study
16 Nov 2020 //
PRNEWSWIRE
Robust effects of VP01 in human idiopathic pulmonary fibrosis lung tissue
25 Sep 2020 //
PRNEWSWIRE
Vicore Pharma doses first COVID-19 patient in the ATTRACT study inIndia
27 Jul 2020 //
CISION
Vicore Pharma`s Drug Candidate VP01 Demonstrates Potential Significant Benefit
22 Jun 2020 //
PRNEWSWIRE
Vicore Pharma bags MHRA nod for COVD-19 trial in record time
01 May 2020 //
PHARMA TIMES
